The development has lead to a product with unique properties branded
as Naturalea Cuvrex™, based on Natexin, active principles with a similar structure
The extract is water soluble and highly purified powder
obtained by a freeze-drying process.
A patent application (n° 102017000028323, March 2017) has been filed to protect the manufacturing process of the extract and its veterinary applications.
The mechanism of action
Cuvrex™ acts in the early stages of inflammation
by suppressing the activity of TNF-α.
The inflammatory response is activated using LPS, a well-known inflammation factor, as can be seen by the increase in the amount of the concentration of TNF-α in the blood sample. The addition of Cuvrex™ extract selectively reduces the inflammatory cytokine TNF-α without affecting IL-6, which is important for mediating the anti-inflammatory effects of exercise. (No LPS: LPS0; +LPS: LPS10; no Natexin: N0; +Natexin: N2000).
In vivo study results suggest that Cuvrex™ helps lowering the exercise-induced stress level perceived by the dog’s organism and in enhancing the dog’s athletic performance. Thus, the extract can be particularly useful for dogs performing prolonged, intense exercise, such as hunting dogs or dogs participating in competitive events, helping to reduce the muscular and joint fatigue.
Effect of Cuvrex™ in dogs undergoing intense and prolonged exercise. The schematic shows the protocol followed for the in vivo study and the time points selected for the analyses. The dogs’ owner reported that their dogs exhibited a better athletic performance at T1. Below, the graph reports HO-1 mRNA levels normalized with the respect to GAPDH, a house-keeping standard reference gene, in samples collected between T0 and T3 and in samples from dogs diagnosed with IBD. Exercise and inflammation increase HO-1 expression, which is decreased when dogs are treated with Cuvrex™, as if their organisms’ stress perception was lower. Studies performed at the University of Bologna, in publication.
These results suggest that Cuvrex™ helps improving gastrointestinal disorders, in particular chronic diarrhoea and vomiting.
Effect of Cuvrex™ in dogs undergoing intense and prolonged exercise. AEA, 2AG, PEA and OEA plasma levels in healthy dogs and in dogs affected by IBD before and after treatment with Cuvrex™ Use of Cuvrex™ normalizes the levels of the endocannabinoid markers. Studies performed at the University of Teramo, in publication.
Clinical IBD activity index (CIBDAI) before (T0) and after (T1) use with Cuvrex™ IBD was classified as moderate or severe and as mild or clinically insignificant before and after use, respectively. Studies performed at the University of Teramo, in publication.